Scientists achieve milestone in animal-free production of biologics
For the first time, scientists have successfully produced sugar-based biologic molecules utilizing bacteria, without the need for animal products. The paper, published in Nature Communications on March 2, describes the production of a common designer polysaccharide, chondroitin sulfate. Read More
Mesoblast gets $110M in financing from investor group
Mesoblast has entered into a subscription agreement to form a limited partnership with SurgCenter Development, a U.S.-based investor group, for a total of $110 million via the issue of 60 million shares. Read More
WuXi AppTec acquires Oxgene, adding to its CGT capabilities
WuXi AppTec has completed the acquisition of Oxgene, a U.K.-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition will allow WuXi to provide its customers with end-to-end support in the creation and development of cell and gene therapies (CGT), according to the company. Read More
Phio, AgonOx partner on T cell-based cancer immunotherapies
Phio Pharmaceuticals and AgonOx have announced a partnership to develop T cell-based cancer immunotherapies. Read More
Pharmaron expands CGT capabilities in U.K.
Pharmaron has purchased Allergan Biologics (ABL) for $118.7 million from AbbVie, expanding its cell and gene therapy (CGT) capabilities in the U.K. Read More
SalioGen closes $20M to finance nonviral gene therapy development
SalioGen Therapeutics has closed $20 million in financing to advance its exact DNA integration technology platform for nonviral gene therapy. Read More
FDA clears Sarepta's Duchenne muscular dystrophy gene therapy
The U.S. Food and Drug Administration has cleared casimersen, an antisense oligonucleotide, for the treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to exon 45 skipping. Read More
Artiva nabs $120M for NK cell therapies
Artiva Biotherapeutics has closed $120 million in financing to advance its natural killer (NK) cell therapy development programs and expand ongoing research and development activities. Read More
Saint-Gobain launches T cell-specific cell culture bags
Saint-Gobain Life Sciences has launched VueLife HP, a new high-permeability cell culture bag designed specifically for T cell-derived therapies. Read More
Jaguar Gene Therapy launches; targets rare genetic diseases
Jaguar Gene Therapy has launched after being in stealth mode with the goal of accelerating the development, manufacturing, and commercialization of novel gene therapy treatments for patients suffering from severe genetic diseases. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter